title: Targeted disruption of the mouse cis-retinol dehydrogenase gene: visual and nonvisual functions.
abstract: It has been proposed that cis-retinol dehydrogenase (cRDH) acts within the body to catalyze the oxidation of 9-cis-retinol, an oxidative step needed for 9-cis-retinoic acid synthesis, the oxidation of 11-cis-retinol [an oxidative step needed for 11-cis-retinal (visual chromophore) synthesis], and 3 alpha-hydroxysteroid transformations. To assess in vivo the physiological importance of each of these proposed actions of cRDH, we generated cRDH-deficient (cRDH-/-) mice. The cRDH-/- mice reproduce normally and appear to be normal. However, the mutant mice do have a mild visual phenotype of impaired dark adaptation. This phenotype is evidenced by electroretinagram analysis of the mice and by biochemical measures of eye levels of retinoid intermediates during recovery from an intense photobleach. Although it is thought that cRDH is expressed in the eye almost solely in retinal pigment epithelial cells, we detected cRDH expression in other retinal cells, including ganglion cells, amacrine cells, horizontal cells, and the inner segments of the rod photoreceptor cells. Aside from the eye, there are no marked differences in retinoid levels in other tissues throughout the body for cRDH-/- compared with cRDH+/+ mice. Moreover, we did not detect any non-visual phenotypic changes for cRDH-/- mice, suggesting that these mice do not have problems in metabolizing 3 alpha-hydroxysteroids.Thus, cRDH may act essentially in the visual cycle but is redundant for catalyzing 9-cis-retinoic acid formation and 3 alpha-hydroxysteroid metabolism.
authors.affiliation: The Institute of Human Nutrition, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
authors.forename: Enyuan
authors.initials: E
authors.lastname: Shang
authors.forename: Katherine
authors.initials: K
authors.lastname: Lai
authors.forename: Alan I
authors.initials: AI
authors.lastname: Packer
authors.forename: Jisun
authors.initials: J
authors.lastname: Paik
authors.forename: William S
authors.initials: WS
authors.lastname: Blaner
authors.forename: Milena
authors.initials: M
authors.lastname: de Morais Vieira
authors.forename: Peter
authors.initials: P
authors.lastname: Gouras
authors.forename: Debra J
authors.initials: DJ
authors.lastname: Wolgemuth
mesh_terms: D000429:Alcohol Oxidoreductases / Q000096:biosynthesis / Q000172:deficiency / Q000235:genetics*; D000077556:Alitretinoin; D000818:Animals; D030801:Animals, Genetically Modified; D003623:Dark Adaptation / Q000235:genetics / Q000502:physiology*; D004596:Electroretinography; D005123:Eye / Q000166:cytology / Q000201:enzymology* / Q000378:metabolism; D018390:Gene Targeting; D006914:Hydroxysteroids / Q000378:metabolism; D017403:In Situ Hybridization; D051379:Mice; D009799:Ocular Physiological Phenomena; D012176:Retinoids / Q000032:analysis / Q000378:metabolism*; D014018:Tissue Distribution; D014212:Tretinoin / Q000378:metabolism*
chemical_list: D006914:Hydroxysteroids; D012176:Retinoids; D000077556:Alitretinoin; D014212:Tretinoin; D000429:Alcohol Oxidoreductases; C022520:retinol dehydrogenase